XNASBCTX
Market cap23mUSD
Dec 23, Last price
0.55USD
1D
-2.57%
1Q
-13.57%
Jan 2017
-98.79%
IPO
-99.53%
Name
Briacell Therapeutics Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
95.26%
Rev. gr., 5y
%
Revenues
0k
Net income
-5m
L-76.40%
CFO
-24m
L+1.61%
Earnings
Mar 17, 2025
Profile
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑07 | 2023‑07 | 2022‑07 | 2021‑07 | 2020‑07 | 2019‑07 | 2018‑07 | 2017‑07 | 2016‑07 | 2015‑07 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 32,808 | 23,288 | 15,304 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (32,808) | (23,288) | (15,304) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 63 | (153) | 31 | |||||||
Tax Rate | ||||||||||
NOPAT | (32,871) | (23,135) | (15,335) | |||||||
Net income | (4,791) -76.40% | (20,302) 75.31% | (11,581) 300.07% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 4,419 | 3,953 | (3,774) | |||||||
BB yield | -26.07% | -2.92% | 2.93% | |||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 1,096 | 29,139 | 31,307 | |||||||
Net debt | (1,281) | (21,251) | (41,042) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (24,126) | (23,745) | (12,484) | |||||||
CAPEX | (457) | |||||||||
Cash from investing activities | (682) | |||||||||
Cash from financing activities | 4,419 | 3,954 | (3,743) | |||||||
FCF | (25,576) | (26,648) | (15,699) | |||||||
| Balance | ||||||||||
Cash | 862 | 21,251 | 41,042 | |||||||
Long term investments | 418 | 2 | 2 | |||||||
Excess cash | 1,281 | 21,251 | 41,042 | |||||||
Stockholders' equity | (13,718) | (11,199) | 5,101 | |||||||
Invested Capital | 12,130 | 36,561 | 36,535 | |||||||
ROIC | ||||||||||
ROCE | 2,064.84% | |||||||||
| EV | ||||||||||
Common stock shares outstanding | 16,455 | 15,620 | 15,494 | |||||||
Price | 1.03 -88.13% | 8.68 4.45% | 8.31 30.66% | |||||||
Market cap | 16,949 -87.50% | 135,579 5.30% | 128,756 347.93% | |||||||
EV | 15,365 | 114,328 | 87,714 | |||||||
EBITDA | (32,724) | (23,273) | (15,289) | |||||||
EV/EBITDA | ||||||||||
Interest | 979 | |||||||||
Interest/NOPBT | ||||||||||